Fueling Endogenous Resolvin Production with High Absorption Omega-3s

The omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have long been known to provide significant health benefits. More recently, a molecular mechanism has emerged that explains how they support a healthy inflammatory response. It’s also clear that to trigger this anti-inflammatory mechanism, a sufficient amount of bioavailable omega-3s must be consumed. This article will discuss a fascinating way omega-3s promote cardiovascular, immune, and cognitive health, among other benefits. It will also discuss the type of supplement your patients need to maximize these benefits.

Resolvins: A Molecular Rationale for Omega-3 Therapy

Resolvins are a family of endogenously generated compounds that produce Specialized Pro-resolving Mediators (SPMs), thereby suppressing inflammation.¹ By fueling resolvins, the omega-3 fatty acids EPA and DHA act as biochemical substrates to produce SPMs.¹ Resolvins originate while inflammation is being resolved in the body.¹ While traditional anti-inflammatories block the origin of inflammation, resolvins derived from EPA and DHA actively shut off the inflammatory response and promote tissue healing.¹

Resolvins have potent actions that may, at least in part, explain why omega-3 fatty acids have dramatic effects in immune and cardiovascular support, as well as other areas of health.^2-4 One trial involving >11,300 patients found that supplementation with Omega-3 fatty acids reduced cardiovascular deaths by 45%.¹

E‑series resolvins (RvE1–3) are generated from eicosapentaenoic acid (EPA),⁵ while D‑series resolvins (RvD1-6) are generated from docosahexaenoic acid (DHA) via lipoxygenase, cyclooxygenase, and cytochrome P450 pathways.⁴ It is interesting to note that aspirin can also generate the production of resolvins.¹ Low-dose aspirin can acetylate the COX-2 enzyme, leading to the generation of “aspirin-triggered” resolvins.¹ Aspirin‑acetylated COX‑2 can shift lipid metabolism toward aspirin-triggered resolvins from DHA and EPA, enhancing pro-resolving mediator formation in some contexts.¹

Simply Taking Omega-3s May Not Increase Resolvins

Supplementing with EPA/DHA, especially at lower doses or with fish oil products that are not bioavailable, does not always translate into higher circulating resolvin levels, as key enzymes such as ALOX15 (15-lipoxygenase-1), which generate resolvin precursors, can be downregulated in some people, especially those with certain health conditions.⁶ Higher doses of EPA (4 grams/day) and DHA (2 grams/day) are often required to increase the plasma levels of resolvin precursors significantly.^7,8

Health Benefits of Fueling Resolvins

Actively enhancing resolvin production through EPA/DHA intake is associated with several clinical benefits:

• Cardiovascular Health: Resolvins help stabilize atherosclerotic plaques and may lower the risk of stroke by reducing vascular inflammation.⁹
• Cognitive and Ocular Function: DHA-derived resolvins and protectins are highly concentrated in the brain and retina, supporting neuroprotection and healthy aging.¹⁰
• Joint and Muscle Support: In conditions like rheumatoid arthritis, increasing EPA and DHA can augment SPM precursor reserves, supporting a healthy inflammatory response in the joints.¹¹
• Metabolic Health: Resolvins may act as “counter-regulators” to the persistent low-grade inflammation often found in adipose (fat) tissue in individuals with obesity.¹²
• Healthy Aging: The means by which omega-3 fatty acids reduce inflammaging, the term used to describe the relationship between age-related diseases and inflammation, may be connected to the ability to enhance resolvins.¹³

The Best Approach to Supplementing Omega-3s

After quantifying our patients’ omega-3 levels with a simple blood test, the next step to enhance resolvin levels is to supplement with a highly absorbable omega-3. High bioavailability increases the likelihood that enough EPA and DHA are delivered to the body to trigger resolvin production. My personal go-to formula includes VESIsorb® EPA, DHA, and CoQ10 to aid in patient compliance and to support mitochondrial function.

As functional medicine providers, we know that the absorption of crucial nutrients is essential to sustain wellness goals. When it comes to optimizing individual EPA and DHA levels, I have incorporated the VESIsorb® delivery system over the last few years, and it has helped my otherwise “stuck patient” better assimilate key nutrients, such as omega-3s, endocannabinoids, and CoQ10. The mechanism of action is that VESIsorb® naturally self-assembles into a colloidal system immediately upon contact with the aqueous environment of the digestive tract. The solubilized nanosized droplets disperse uniformly, diffuse across the unstirred water layer, and then deliver the bioactives to the intestinal system. Patented VESIsorb^® technology is clinically proven to provide up to 6X greater bioavailability across multiple PK studies in human subjects.¹⁵

This increased absorption of omega-3s can help patients obtain their essential fatty acids, boosting resolvin levels and supporting a healthy inflammatory response. Ultimately, inflammaging is very real and well-documented in the peer-reviewed literature. I educate my patients that chronic and systemic inflammation is an accelerant of existing pathophysiology and a disruptor of homeostasis.

Disclaimer: Dr. Chris D. Meletis is an independent educator in the nutraceutical space, including TruGen3, which offers VESIsorb.

References:

1. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196(8):1025-1037.
2. Rueda-Munguía M, Luévano-Martínez LA, García-Rivas G, Castillo EC, Lozano O. Macrophages: their role in immunity and their relationship with fatty acids in health and disease. Front Immunol. 2025;16:1694892.patients obtain their essential fatty acids, boost
3. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346(15):1113-1118.
4. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897-1903.
5. Tang M, Dang R, Liu S, et al. Ω-3 fatty acids-supplementary in gestation alleviates neuroinflammation and modulates neurochemistry in rats. Lipids Health Dis. 2018;17(1):247.
6. Tian R, Zuo X, Jaoude J, Mao F, Colby J, Shureiqi I. ALOX15 as a suppressor of inflammation and cancer: Lost in the link. Prostaglandins Other Lipid Mediat. 2017;132:77-83.
7. Lamon-Fava S, So J, Mischoulon D, et al. Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2021;164:102219.
8. Sears B. Appropriate doses of omega-3 fatty acids for therapeutic results CellR4. 2018;6(4):e2578.
9. Lipscomb M, Salfate Del Rio I, Eid M, et al. Resolvin D2 limits senescent cell accumulation in atherosclerotic plaques. Vascul Pharmacol. 2025;160:107527.
10. Bazan NG, Rodriguez de Turco EB, Gordon WC. Pathways for the uptake and conservation of docosahexaenoic acid in photoreceptors and synapses: biochemical and autoradiographic studies. Can J Physiol Pharmacol. 1993;71(9):690-698.
11. Möller I, Rodas G, Villalón JM, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study. J Transl Med. 2023;21(1):423.
12. Al-Shaer AE, Regan J, Buddenbaum N, et al. Enriched Marine Oil Supplement Increases Specific Plasma Specialized Pro-Resolving Mediators in Adults with Obesity. J Nutr. 2022;152(7):1783-1791.
13. Doyle R, Sadlier DM, Godson C. Pro-resolving lipid mediators: Agents of anti-ageing? Semin Immunol. 2018;40:36-48.
14. Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb(®) Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects. Molecules. 2019;24(16).
15. Liu ZX, Artmann C. Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Altern Ther Health Med. 2009;15(2):42-46.